 Sarit Polsky
Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy in Diabetics | 12 | 2023 | 82 | 6.670 |
Why?
| | Diabetes Mellitus, Type 1 | 33 | 2024 | 3254 | 4.700 |
Why?
| | Blood Glucose Self-Monitoring | 19 | 2024 | 500 | 3.320 |
Why?
| | Blood Glucose | 26 | 2024 | 1824 | 3.300 |
Why?
| | Hypoglycemic Agents | 11 | 2023 | 1008 | 2.210 |
Why?
| | Insulin Infusion Systems | 10 | 2023 | 296 | 1.900 |
Why?
| | Insulin | 13 | 2023 | 2082 | 1.490 |
Why?
| | Hypoglycemia | 6 | 2021 | 386 | 1.440 |
Why?
| | Pregnancy | 19 | 2023 | 5548 | 1.350 |
Why?
| | Alcohol Drinking | 4 | 2020 | 648 | 0.990 |
Why?
| | Pregnancy Outcome | 7 | 2023 | 336 | 0.950 |
Why?
| | Diabetes, Gestational | 4 | 2023 | 282 | 0.900 |
Why?
| | Postnatal Care | 2 | 2021 | 67 | 0.850 |
Why?
| | Preconception Care | 1 | 2021 | 31 | 0.740 |
Why?
| | Diabetes Complications | 2 | 2020 | 212 | 0.730 |
Why?
| | Female | 41 | 2024 | 59913 | 0.720 |
Why?
| | Pilot Projects | 5 | 2021 | 1377 | 0.620 |
Why?
| | Tobacco Use | 1 | 2018 | 59 | 0.610 |
Why?
| | Spices | 2 | 2014 | 5 | 0.600 |
Why?
| | Hyperglycemia | 4 | 2022 | 294 | 0.580 |
Why?
| | Pregnant Women | 4 | 2021 | 132 | 0.570 |
Why?
| | Fear | 1 | 2019 | 297 | 0.560 |
Why?
| | Postprandial Period | 2 | 2019 | 88 | 0.560 |
Why?
| | Food Preferences | 2 | 2014 | 108 | 0.550 |
Why?
| | Humans | 49 | 2024 | 115587 | 0.540 |
Why?
| | Obesity | 5 | 2019 | 2517 | 0.530 |
Why?
| | Adult | 28 | 2024 | 30718 | 0.490 |
Why?
| | Lunch | 1 | 2014 | 7 | 0.490 |
Why?
| | Meat Products | 1 | 2014 | 25 | 0.480 |
Why?
| | Breakfast | 1 | 2014 | 14 | 0.480 |
Why?
| | Cardiovascular Diseases | 4 | 2022 | 1724 | 0.460 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2020 | 2098 | 0.450 |
Why?
| | Postoperative Care | 1 | 2015 | 222 | 0.440 |
Why?
| | Insulin Resistance | 3 | 2022 | 1078 | 0.430 |
Why?
| | Diabetes Mellitus | 3 | 2021 | 906 | 0.430 |
Why?
| | Preoperative Care | 1 | 2015 | 318 | 0.420 |
Why?
| | Hypertension | 1 | 2020 | 1064 | 0.420 |
Why?
| | Bariatric Surgery | 1 | 2015 | 162 | 0.410 |
Why?
| | Comorbidity | 2 | 2021 | 1473 | 0.400 |
Why?
| | Weight Loss | 4 | 2019 | 633 | 0.380 |
Why?
| | Insulin Aspart | 2 | 2022 | 26 | 0.380 |
Why?
| | Young Adult | 13 | 2022 | 10470 | 0.360 |
Why?
| | Diabetic Neuropathies | 2 | 2022 | 79 | 0.360 |
Why?
| | Substance-Related Disorders | 1 | 2018 | 950 | 0.360 |
Why?
| | Feeding Behavior | 1 | 2014 | 573 | 0.330 |
Why?
| | Prediabetic State | 1 | 2011 | 225 | 0.300 |
Why?
| | Diabetic Nephropathies | 2 | 2020 | 234 | 0.280 |
Why?
| | Prenatal Care | 2 | 2021 | 257 | 0.270 |
Why?
| | Middle Aged | 19 | 2022 | 26999 | 0.270 |
Why?
| | Gastric Bypass | 2 | 2019 | 94 | 0.260 |
Why?
| | Risk Factors | 9 | 2022 | 8697 | 0.250 |
Why?
| | Registries | 4 | 2020 | 1770 | 0.230 |
Why?
| | Weight Reduction Programs | 2 | 2015 | 91 | 0.230 |
Why?
| | Biomedical Technology | 1 | 2023 | 41 | 0.220 |
Why?
| | Off-Label Use | 1 | 2023 | 52 | 0.210 |
Why?
| | Infant, Newborn | 3 | 2023 | 5077 | 0.210 |
Why?
| | Insulin Lispro | 1 | 2022 | 35 | 0.210 |
Why?
| | Male | 20 | 2024 | 55949 | 0.210 |
Why?
| | Aged | 13 | 2022 | 19251 | 0.200 |
Why?
| | Diabetic Retinopathy | 1 | 2024 | 149 | 0.200 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2022 | 27 | 0.200 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2021 | 19 | 0.200 |
Why?
| | United States | 8 | 2021 | 12295 | 0.200 |
Why?
| | Technology | 1 | 2021 | 79 | 0.190 |
Why?
| | Overweight | 2 | 2015 | 469 | 0.190 |
Why?
| | Parity | 1 | 2020 | 99 | 0.180 |
Why?
| | Allopurinol | 1 | 2020 | 55 | 0.180 |
Why?
| | Xanthine Oxidase | 1 | 2020 | 72 | 0.180 |
Why?
| | Glomerular Filtration Rate | 2 | 2020 | 605 | 0.180 |
Why?
| | Epidemics | 1 | 2021 | 70 | 0.170 |
Why?
| | Longitudinal Studies | 3 | 2024 | 2416 | 0.170 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2020 | 25 | 0.170 |
Why?
| | Diabetic Ketoacidosis | 1 | 2021 | 159 | 0.170 |
Why?
| | Uric Acid | 1 | 2020 | 150 | 0.170 |
Why?
| | Retrospective Studies | 8 | 2024 | 12608 | 0.170 |
Why?
| | Appetite Regulation | 1 | 2019 | 26 | 0.160 |
Why?
| | Adolescent | 8 | 2022 | 17889 | 0.160 |
Why?
| | Diet, Reducing | 1 | 2019 | 79 | 0.160 |
Why?
| | Postpartum Period | 1 | 2021 | 281 | 0.160 |
Why?
| | Treatment Outcome | 4 | 2021 | 9159 | 0.160 |
Why?
| | Physicians, Primary Care | 1 | 2021 | 222 | 0.150 |
Why?
| | Eczema | 1 | 2018 | 82 | 0.150 |
Why?
| | Telemetry | 1 | 2017 | 35 | 0.140 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 757 | 0.140 |
Why?
| | Insulin, Short-Acting | 1 | 2016 | 4 | 0.140 |
Why?
| | Glucose | 1 | 2021 | 904 | 0.140 |
Why?
| | HIV Infections | 1 | 2011 | 2473 | 0.140 |
Why?
| | Sex Characteristics | 2 | 2018 | 641 | 0.140 |
Why?
| | Infusions, Subcutaneous | 1 | 2016 | 19 | 0.130 |
Why?
| | Body Mass Index | 3 | 2019 | 1971 | 0.130 |
Why?
| | Self Care | 1 | 2018 | 354 | 0.130 |
Why?
| | Taste | 2 | 2014 | 208 | 0.130 |
Why?
| | Pancreas, Artificial | 1 | 2016 | 68 | 0.120 |
Why?
| | Cheese | 1 | 2014 | 5 | 0.120 |
Why?
| | Gastroplasty | 1 | 2014 | 26 | 0.120 |
Why?
| | Delphi Technique | 1 | 2015 | 164 | 0.120 |
Why?
| | Disease Management | 1 | 2018 | 563 | 0.120 |
Why?
| | Life Style | 2 | 2023 | 429 | 0.120 |
Why?
| | Pleasure | 1 | 2014 | 18 | 0.120 |
Why?
| | Quality of Life | 2 | 2023 | 2385 | 0.120 |
Why?
| | Chickens | 1 | 2014 | 183 | 0.120 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 250 | 0.110 |
Why?
| | Skin | 1 | 2018 | 662 | 0.110 |
Why?
| | Vegetables | 1 | 2014 | 133 | 0.110 |
Why?
| | Menopause | 1 | 2016 | 262 | 0.110 |
Why?
| | Community Health Services | 1 | 2014 | 212 | 0.110 |
Why?
| | Models, Organizational | 1 | 2013 | 143 | 0.100 |
Why?
| | Program Evaluation | 2 | 2014 | 836 | 0.100 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 4435 | 0.100 |
Why?
| | Glucose Tolerance Test | 2 | 2011 | 344 | 0.100 |
Why?
| | Dietary Fats | 1 | 2014 | 289 | 0.100 |
Why?
| | Hospitalization | 1 | 2021 | 1765 | 0.100 |
Why?
| | Cohort Studies | 3 | 2020 | 4944 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1216 | 0.100 |
Why?
| | Internet | 1 | 2016 | 602 | 0.100 |
Why?
| | Feasibility Studies | 1 | 2013 | 741 | 0.090 |
Why?
| | Laparoscopy | 1 | 2014 | 400 | 0.090 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2022 | 101 | 0.090 |
Why?
| | Cross-Over Studies | 2 | 2022 | 434 | 0.080 |
Why?
| | Aged, 80 and over | 5 | 2021 | 6417 | 0.080 |
Why?
| | Risk Assessment | 1 | 2017 | 2987 | 0.080 |
Why?
| | Telemedicine | 1 | 2016 | 667 | 0.070 |
Why?
| | Diabetic Angiopathies | 2 | 2020 | 244 | 0.070 |
Why?
| | Double-Blind Method | 2 | 2022 | 1660 | 0.070 |
Why?
| | Diet | 1 | 2014 | 1072 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 4665 | 0.070 |
Why?
| | Rural Health Services | 1 | 2007 | 93 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2013 | 844 | 0.070 |
Why?
| | Metformin | 1 | 2009 | 278 | 0.070 |
Why?
| | Health Behavior | 1 | 2009 | 707 | 0.060 |
Why?
| | Bionics | 1 | 2022 | 11 | 0.050 |
Why?
| | Prognosis | 2 | 2021 | 3339 | 0.050 |
Why?
| | Child | 4 | 2022 | 18488 | 0.050 |
Why?
| | Bromocriptine | 1 | 2022 | 27 | 0.050 |
Why?
| | Energy Intake | 2 | 2019 | 414 | 0.050 |
Why?
| | Demography | 1 | 2021 | 261 | 0.050 |
Why?
| | Creatinine | 1 | 2022 | 430 | 0.050 |
Why?
| | Aspirin | 1 | 2023 | 326 | 0.050 |
Why?
| | Wounds and Injuries | 1 | 2007 | 725 | 0.040 |
Why?
| | Renin-Angiotensin System | 1 | 2020 | 72 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2023 | 432 | 0.040 |
Why?
| | Peptide YY | 1 | 2019 | 13 | 0.040 |
Why?
| | Satiation | 1 | 2019 | 22 | 0.040 |
Why?
| | Sex Factors | 2 | 2018 | 1736 | 0.040 |
Why?
| | Treatment Failure | 1 | 2020 | 332 | 0.040 |
Why?
| | Ghrelin | 1 | 2019 | 33 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 4440 | 0.040 |
Why?
| | Appetite | 1 | 2019 | 53 | 0.040 |
Why?
| | Lipids | 1 | 2022 | 588 | 0.040 |
Why?
| | Albuminuria | 1 | 2019 | 164 | 0.040 |
Why?
| | Income | 1 | 2019 | 170 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 241 | 0.040 |
Why?
| | Population Surveillance | 1 | 2021 | 395 | 0.040 |
Why?
| | Educational Status | 1 | 2019 | 413 | 0.040 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 115 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2016 | 84 | 0.030 |
Why?
| | Medicare | 1 | 2021 | 666 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2021 | 576 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 644 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 2800 | 0.030 |
Why?
| | Animals | 1 | 2014 | 32102 | 0.030 |
Why?
| | Meals | 1 | 2014 | 101 | 0.030 |
Why?
| | Focus Groups | 1 | 2014 | 393 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1334 | 0.030 |
Why?
| | Age Factors | 1 | 2019 | 2907 | 0.030 |
Why?
| | Obesity, Morbid | 1 | 2014 | 199 | 0.020 |
Why?
| | Health Education | 1 | 2014 | 325 | 0.020 |
Why?
| | Social Support | 1 | 2014 | 537 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1650 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 3466 | 0.020 |
Why?
| | Placebos | 1 | 2009 | 198 | 0.020 |
Why?
| | Prospective Studies | 1 | 2020 | 6264 | 0.020 |
Why?
| | Cholesterol, HDL | 1 | 2009 | 185 | 0.020 |
Why?
| | Glucose Intolerance | 1 | 2009 | 137 | 0.020 |
Why?
| | Kenya | 1 | 2007 | 98 | 0.020 |
Why?
| | Accidental Falls | 1 | 2007 | 151 | 0.020 |
Why?
| | Violence | 1 | 2007 | 202 | 0.020 |
Why?
| | Colorado | 1 | 2014 | 4113 | 0.020 |
Why?
| | Time Factors | 1 | 2015 | 6165 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2014 | 2161 | 0.010 |
Why?
| | Burns | 1 | 2007 | 242 | 0.010 |
Why?
| | Incidence | 1 | 2009 | 2335 | 0.010 |
Why?
|
|
Polsky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|